Our Strategy

Grupo Fleury growth goes through the following fronts to be explored in the healthcare value chain:

  • Organic expansion in PSCs business. Guidance of 73 to 90 new PSCs between 2017 and 2021 (54 PSCs already delivered)
  • Continue to be the leader of genomics segment in Brazil and increase revenue participation from 1% (2017) to 5% (2022)
  • New offerings beyond diagnostics: primary care, healthcare coordination, drug infusion, orthopedic procedures and others
  • Company’s digital transformation: medical knowledge, clients relationship, back office processes and others
  • Strong pillar on innovation: R&D, startups and technical partnerships
  • M&A Opportunities to become the market consolidator in the diagnostic segment 19

To know more about the Grupo Fleury strategy, access the Institutional and the Fleury Investor‘s Day presentations.